FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
Dateline City:
KENILWORTH, N.J.
Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the U.S. Food and Drug Administration (FDA) has accepted
for review a supplemental Biologics License Application (sBLA) for
KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. Merck
is seeking approval for KEYTRUDA, at the currently approved dose of 2
mg/kg every three weeks, for the first-line treatment of unresectable or
metastatic melanoma patients.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879An Phan, 908-255-6325
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
More News: Cancer & Oncology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Grants | Melanoma | Merck | Skin Cancer | Yervoy